Sunday, May 02, 2021 7:47:59 AM
about crossover yes it is ethically correct to have a crossover and easier to recruit patients, but that was not what I wrote anything about. it was a comment to compare things that should not be compared. So if you think it's fine to compare our blinded (or unblinded) data with SOC then be my guest .. but it is just plane wrong ..
as to why one has placebo vs. teatment and one must show stat. Sig. is to eliminate external factors for the effect teatment hopefully exhibits. Said in laymen words, so people understand it. if one has not understood it then he one did not understand the core of medical trials like this .. and if that is not the case why then at all compare with control in other trials .. come on ..
and as for the hold .. pure speculation .. no one knows i.. but I think and hope it is due to pseudoprogression .. and the reason is that the timeline fits nicely in relationship when LL started to put more focus on it.
as to why one has placebo vs. teatment and one must show stat. Sig. is to eliminate external factors for the effect teatment hopefully exhibits. Said in laymen words, so people understand it. if one has not understood it then he one did not understand the core of medical trials like this .. and if that is not the case why then at all compare with control in other trials .. come on ..
and as for the hold .. pure speculation .. no one knows i.. but I think and hope it is due to pseudoprogression .. and the reason is that the timeline fits nicely in relationship when LL started to put more focus on it.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
